Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 127-134

  Hoppichler, Fritz ^a   Kraft, Hans G ^b   Sandholzer, Christoph ^b   Lechleitner, Monika ^a   Patsch, Josef R ^a   Utermann, Gerd ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Apolipoprotein(a); Density gradient ultracentrifugation; Lipoprotein(a); Postprandial lipoprotein metabolism; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; TRIACYLGLYCEROL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAT INTAKE; HUMAN; LIPID METABOLISM; MALE; PRIORITY JOURNAL;

EID: 0029881691     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05803-0     Document Type: Article

References (34)

1. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904.
2. 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 1993;90:11643.
3. Bersot TP, Innerarity TL, Pitas RE, Rail SC, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein(a) and that cause lipid accumulation in macrophages. J Clin Invest 1986;77:622.
4. Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM. Relationship between apo(a) isoforms and Lp(a) density in subjects with different apo(a) phenotype: a study before and after fat meal. J Lipid Res 1991;32:679.
5. Scanu AM, Edelstein C, Fless GM, Eisenbart J, Sitrin M, Kasawa B, Hinman J. Postprandial lipoprotein(a) response to a single meal containing either saturated or ω-3 polyunsaturated fatty acids in subjects with hypo-α-lipoproteinemia. Metabolism 1992;12:1361.
6. Cohn JS, Lam CWK, Sullivan DR, Hensley WJ. Plasma lipoprotein distribution of apolipoprotein(a) in fed and fasted states. Atherosclerosis 1991;90:59.
7. Lackner C, Boerwinkle E, Leffert CC, Rahming T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2153.
8. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes, inheridance and relation to Lp(a) lipoprotein concentration in plasma. J Clin Invest 1987;80:458.
9. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds). The metabolic and molecular bases on inherited disease, 7th Edn, chapter 58, volume II. New York: McGravv-Hill, 1995;1887-1912.
10. Jürgens G, Költringer P. Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of carotid arteries. Chem Phys Lipids 1994;67/68:429.
11. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111.
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52.
13. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992;90:220.
14. Corsetti JP, Sterry JA, Spareks JD, Sparks CE, Weintraub M. Effects of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem 1991;37:1191.
15. Cardoso GC, Posadas C, Orvananos OO, Peniche C, Zamora J, Aguilar R, Holguin JA, Raynaud AS, Morrisett JD, Guevara J Jr. Long distance runners and body-builders exhibit elevated levels of lipoprotein(a). Chem Phys Lipids 1994;67,68:207.
16. Fless GM, Snyder M, Lewis G, Scanu AM: Effects of an acute fat load on the total level and plasma distribution of apo B-100-apo(a) complex. Arteriosclerosis 1988;8:608a.
17. Fless GM, Pfaffinger DJ, Eisenbart JD, Scanu AM. Solubility, immunochemical and lipoprotein binding properties of apo B-100-apo(a), the protein moiety of lipoprotein(a). J Lipid Res 1990;31:909.
18. Selinger E, Dallongeville J, Davignon J. Lp(a) is present in plasma of density < 1.006 g/ml in Hypertriglyceridemia. Arteriosclerosis 1990;10(5):756a.
19. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dünn JK, Gotto AM, Jr., Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992;12:1336.
20. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM, Jr. Inverse relationship between blood levels of high density lipoprotein 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449.
21. Kronenberg F, Lobentanz E, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994;35:1318.
22. Redgrave RG, Roberts DCK, West CE. Separation of plasma lipoproteins by density-gradient-ultracentrifugation. Anal Biochem 1975;65:42.
23. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111.
24. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;300:132.
25. Gonzales-Gronow M, Edelberg JN, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 1989;28:2374.
26. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301.
27. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
28. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a) fibrin binding and plasminogen activation. Arteriosclerosis 1990;10:240.
29. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism, Proc Natl Acad Sci USA 1992;89:10193.
30. Scanu AM, Pfaffinger D, Edelstein C. Post-prandial Lp(a): identification of a triglyceride-rich particle. Chem Phys Lipids 1994;67,68:193.
31. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995;1:256.
32. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655.
33. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of Lp(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;167:4143.
34. Sandholzer C, Feussner G, Brunzell J, Utermann G. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia: No evidence for a triglyceride-rich precursor of lipoprotein(a). J Clin Invest 1992;90:1958.